3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
27
Prostatic Neoplasms
22
Stomach Neoplasms
13
Squamous Cell Carcinoma of Head and Neck
12
Neoplasms
10
Lung Neoplasms
10
Urinary Bladder Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Squamous Cell
6
Non-Muscle Invasive Bladder Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Transitional Cell
5
Adenocarcinoma
5
Oropharyngeal Neoplasms
4
Sarcoma
3
Prostatic Neoplasms, Castration-Resistant
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Metastatic Castration-resistant Prostate Cancer
3
HER2-positive Breast Cancer
3
Esophageal Squamous Cell Carcinoma
3
Endometrial Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Vaccinia
2
Recurrence
2
Peritoneal Neoplasms
2
Metastatic Castration-Resistant Prostate Cancer
2
Interventions
Paclitaxel
2
tremelimumab
1
trastuzumab deruxtecan
1
poly ICLC
1
pembrolizumab
1
osimertinib
1
eribulin
1
durvalumab
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Radiotherapy
1
Peptides
1
Doxorubicin
1
Docetaxel
1
Carboplatin
1
Capecitabine
1
Bevacizumab
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Docetaxel
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled